Hennion & Walsh Asset Management Inc. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV

Key Points

• Hennion & Walsh Asset Management raised its stake in KalVista by 93.6% in Q4 to 341,819 shares (about 0.68% ownership), valued at roughly $5.52 million.
• Wall Street sentiment is broadly positive — seven Buy vs. one Sell — giving KalVista a consensus rating of "Moderate Buy" and an average price target of $32.60, versus the stock's recent open near $18.36.
• Company insiders have been net sellers, disposing of 248,009 shares worth about $4.21 million in the past 90 days; insiders now hold 4.30% of the stock.

Hennion & Walsh Asset Management Inc. raised its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 93.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 341,819 shares of the specialty pharmaceutical company's stock after purchasing an additional 165,236 shares during the quarter. Hennion & Walsh Asset Management Inc. owned 0.68% of KalVista Pharmaceuticals worth $5,520,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of KALV. The Manufacturers Life Insurance Company grew its stake in KalVista Pharmaceuticals by 5.9% in the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company's stock worth $165,000 after purchasing an additional 818 shares in the last quarter. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock valued at $46,000 after buying an additional 1,292 shares in the last quarter. Rhumbline Advisers lifted its holdings in KalVista Pharmaceuticals by 2.8% during the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company's stock worth $615,000 after buying an additional 1,458 shares during the last quarter. Profund Advisors LLC lifted its holdings in KalVista Pharmaceuticals by 25.9% during the 3rd quarter. Profund Advisors LLC now owns 12,613 shares of the specialty pharmaceutical company's stock worth $154,000 after buying an additional 2,593 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of KalVista Pharmaceuticals by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock worth $281,000 after acquiring an additional 2,939 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KALV. HC Wainwright boosted their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a "buy" rating in a research report on Friday, January 9th. TD Cowen restated a "buy" rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Needham & Company LLC upped their target price on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a "buy" rating in a report on Wednesday, March 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Citizens Jmp cut their price target on KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating on the stock in a report on Thursday, March 26th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, KalVista Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $32.60.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $18.36 on Tuesday. The company has a 50-day moving average of $16.12 and a 200-day moving average of $14.47. The firm has a market cap of $940.40 million, a price-to-earnings ratio of -4.65 and a beta of -0.35. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.23 and a twelve month high of $19.95.

Insider Transactions at KalVista Pharmaceuticals

In other news, CFO Brian Piekos sold 1,767 shares of the firm's stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the sale, the chief financial officer owned 13,762 shares of the company's stock, valued at $214,274.34. This trade represents a 11.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Paul K. Audhya sold 5,354 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $83,361.78. Following the completion of the sale, the insider directly owned 138,983 shares of the company's stock, valued at approximately $2,163,965.31. This represents a 3.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 248,009 shares of company stock worth $4,213,467. 4.30% of the stock is currently owned by insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.